International Medical Devices, Inc. v. Robert Cornell

Summary

The United States District Court for the Central District of California denies Defendants’ renewed motion for judgment as a matter of law and motion for a new trial. The order addresses trade secret misappropriation, trademark infringement, counterfeit marking, breach of contract, patent invalidity, and claim-construction arguments arising from the development and marketing of a competing penile implant product. The court concludes that sufficient evidence supported the jury’s verdicts and that Defendants did not establish grounds for a new trial.

Holdings

1. The evidence was legally sufficient for the jury to find that Plaintiffs' four alleged trade secrets were not generally known, had independent economic value, and were protected through reasonable efforts; judgment as a matter of law and a new trial were therefore unwarranted.
2. The evidence supported the jury's finding that Cornell misappropriated Plaintiffs' trade secrets by acquiring them during training subject to an NDA and using them to develop Augmenta; neither judgment as a matter of law nor a new trial was warranted.
3. The evidence permitted reasonable jurors to find that Mische, Nichols, HMT, Finger, and Wang knew or had reason to know that trade-secret information was derived from Cornell or another person owing Plaintiffs a duty of secrecy, and that some defendants used the information; judgment as a matter of law and a new trial were unwarranted.
4. Plaintiffs presented sufficient evidence of harm, including loss of secrecy, loss of commercial protection, and inability to commercialize the concepts with protection; judgment as a matter of law and a new trial were unwarranted.
5. The evidence supported the trademark-infringement verdict because Plaintiffs presented evidence of harm and actual customer confusion resulting from Defendants' use of the Penuma mark; the motion was denied.
6. The evidence supported findings that the Penuma mark was counterfeit, Cornell knew it was counterfeit, its use was likely to confuse, and the mark was used in connection with an offer for sale even though no actual sale or distribution occurred.
7. The evidence supporting trade-secret misappropriation also supported the jury's finding that Cornell breached the NDA; judgment as a matter of law and a new trial were unwarranted.
8. The evidence was sufficient for the jury to find that Plaintiffs' trade secrets significantly contributed to claims in the challenged patents, and Defendants failed to show that the clear weight of the evidence made the patent-invalidity verdict erroneous.
9. Defendants could not obtain a new trial based on the court's alleged failure to construe patent claims because they had not previously objected and had affirmatively taken the position that the relevant issues should be decided by the jury.

Questions Presented

1. Whether Defendants were entitled to judgment as a matter of law or a new trial because Plaintiffs failed to prove that the four alleged trade secrets were secret, had independent economic value, or were subject to reasonable efforts to maintain secrecy.
2. Whether the evidence was legally insufficient to establish that Cornell and the other Defendants individually misappropriated Plaintiffs' trade secrets.
3. Whether Plaintiffs presented sufficient evidence of harm resulting from the alleged trade-secret misappropriation.
4. Whether the evidence was insufficient to support the jury's trademark-infringement verdict because Plaintiffs did not prove damages or likelihood of confusion.
5. Whether the evidence was insufficient to support the counterfeit-mark verdict because the mark was not counterfeit, Defendants lacked the requisite knowledge, confusion was not shown, or the mark was not used in connection with an offer for sale.
6. Whether the evidence was insufficient to support the breach-of-contract verdict because the information was publicly available, already known, or not confidential under the nondisclosure agreement.
7. Whether Plaintiffs failed to prove their patent-invalidity claims by clear and convincing evidence because the trade secrets were not significant inventive aspects of the patents.
8. Whether Defendants were entitled to a new trial based on the court's alleged failure to construe patent claims.

Disposition

other